GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM Vaccine Co Ltd (HKSE:06660) » Definitions » Operating Income

AIM Vaccine Co (HKSE:06660) Operating Income : HK$-315 Mil (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is AIM Vaccine Co Operating Income?

AIM Vaccine Co's Operating Income for the six months ended in Jun. 2024 was HK$-140 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-315 Mil.

Warning Sign:

AIM Vaccine Co Ltd has never been profitable in the past 3 years. It lost money every year.

Operating Margin % is calculated as Operating Income divided by its Revenue. AIM Vaccine Co's Operating Income for the six months ended in Jun. 2024 was HK$-140 Mil. AIM Vaccine Co's Revenue for the six months ended in Jun. 2024 was HK$578 Mil. Therefore, AIM Vaccine Co's Operating Margin % for the quarter that ended in Jun. 2024 was -24.23%.

AIM Vaccine Co's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. AIM Vaccine Co's annualized ROC % for the quarter that ended in Jun. 2024 was -3.76%. AIM Vaccine Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -6.67%.


AIM Vaccine Co Operating Income Historical Data

The historical data trend for AIM Vaccine Co's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM Vaccine Co Operating Income Chart

AIM Vaccine Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
186.56 575.16 -738.92 -425.56 -492.97

AIM Vaccine Co Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Operating Income Get a 7-Day Free Trial -137.79 -294.30 -318.25 -174.72 -140.11

AIM Vaccine Co Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-315 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AIM Vaccine Co  (HKSE:06660) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

AIM Vaccine Co's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-280.21 * ( 1 - 8.82% )/( (6704.178 + 6888.373)/ 2 )
=-255.495478/6796.2755
=-3.76 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7943.017 - 1368.958 - ( 805.475 - max(0, 2845.902 - 2715.783+805.475))
=6704.178

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7881.725 - 1459.722 - ( 705.5 - max(0, 3134.848 - 2668.478+705.5))
=6888.373

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

AIM Vaccine Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-278.42/( ( (3942.226 + max(260.949, 0)) + (3862.837 + max(278.217, 0)) )/ 2 )
=-278.42/( ( 4203.175 + 4141.054 )/ 2 )
=-278.42/4172.1145
=-6.67 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1161.743 + 557.674 + 46.199) - (1368.958 + 0 + 135.709)
=260.949

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1243.217 + 525.431 + 44.803) - (1459.722 + 0 + 75.512)
=278.217

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

AIM Vaccine Co's Operating Margin % for the quarter that ended in Jun. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-140.105/578.295
=-24.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


AIM Vaccine Co Operating Income Related Terms

Thank you for viewing the detailed overview of AIM Vaccine Co's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM Vaccine Co Business Description

Traded in Other Exchanges
N/A
Address
91 Jianguo Road, 25th Floor, Building A, Chaoyang, Beijing, CHN
AIM Vaccine Co Ltd is a top full-chain vaccine corporation in China with businesses covering the whole industrial chain ranging from research and development to manufacturing and commercialization. The Vaccine products include Recombinant HBV Vaccines, Freeze-dried Human Rabies Vaccine, Inactivated HAV Vaccines, Group A, C, Y, and W135 MPSV, Bivalent Inactivated HFRS Vaccine, and Mumps Vaccine. It generates all of its revenues in the PRC.
Executives
Zhao Yin Jin Rong Kong Gu Shen Zhen You Xian Gong Si 2201 Interest of corporation controlled by you
Zhao Shang Yin Xing Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Zi Ben Guan Li Shen Zhen You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Shi Bei Lun Qu Guo You Zi Ben Yun Ying You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Bao Shui Qu Kong Gu You Xian Gong Si 2101 Beneficial owner
Yong Zhou Qing Teng Mao Yi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Li Lihua 2201 Interest of corporation controlled by you
Shang Hai Xun Jing Qi Ye Guan Li Zhong Xin You Xian He Huo 2201 Interest of corporation controlled by you
Zhu Hai Tong Dao Ming Tian Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Mei Hua Sheng Wu Ke Ji Ji Tuan Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
La Sa Mei Hua Sheng Wu Tou Zi Kong Gu You Xian Gong Si 2101 Beneficial owner
Xi Zang Dong Fang Zhi Hui Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Shen Yang Qian Qian Qi Ye Guan Li Zi Xun You Xian Gong Si 2101 Beneficial owner

AIM Vaccine Co Headlines

No Headlines